HABERMAN ASSOCIATES NEWS PAGE ARCHIVE
2005 News
December 22, 2005: PharmaWeek published an article by Allan B. Haberman, Ph.D. in its December 21, 2005 issue, entitled "Breaking the Obesity Barrier: Near-Term Prospects for Breakthrough Treatments". PharmaWeek is a new weekly e-newsletter published by Cambridge Healthtech Institute. Dr. Haberman’s article is based in part on discussions at the Obesity Summit Conference sponsored by the Massachusetts Biotechnology Council (MBC) at Northeastern University in Boston in November 2005.

December 5, 2005: Allan B. Haberman, Ph.D. served on the faculty of a course entitled “Cardiovascular Drug Development”, offered by the Pharmaceutical Education and Research Institute (PERI) on December 5-7, 2005 in Boston, MA. Dr. Haberman’s presentation was entitled “New Therapeutic Approaches to Cardiovascular Disease Management”. PERI is a not-for-profit organization that provides training and continuing education for pharmaceutical industry professionals.

December 1, 2005: Genetic Engineering News published an article by Allan B. Haberman, Ph.D. in its December issue, entitled "Strategies to Move Beyond Target Validation: Targets and Druggability for Small and Large Molecule Drugs". This article is based on Dr. Haberman's book-length report, Powering Drug Discovery through Target Evaluation: Moving Beyond the Validation Paradigm, published on August 18, 2005 by Cambridge Healthtech Advisors (CHA).

August 18, 2005: Cambridge Healthtech Advisors (CHA) announced the publication of a new book-length report, Powering Drug Discovery through Target Evaluation: Moving Beyond the Validation Paradigm, by Allan B. Haberman, Ph.D. The pharmaceutical industry is faced with steadily growing drug development costs, depleted pipelines, and low output of new molecular entities. The current paradigm of target validation is coming under increasing scrutiny as a major factor in the low productivity of pharmaceutical R&D. This report reviews new target evaluation technologies, and strategies aimed at moving beyond the current target validation paradigm in order to improve R&D productivity. It is essential reading for all R&D managers striving to make genomics-based drug discovery more effective.

For more information on the report, or to order it, see the CHA website.
 

June 24, 2005: Allan B. Haberman, Ph.D. was interviewed for and quoted in an article written by Catherine Arnst, entitled “Biotech, Finally” in the June 13, 2005 issue of Business Week. The article focuses on the pharmaceutical and biotechnology industry and some of its recent achievements and challenges.

Dr. Haberman’s letter to the editor, which was in response to that article, was published in the Readers Report section of the July 4, 2005 edition of Business Week. The focus of the letter was the role of biotechnology and pharmaceutical companies, and of academia, in progress in drug discovery and development.